Globus Medical Cuts 2026 Revenue Guidance to $3.09B, Adds $500M to Buyback
GMED sits 33% above its 52-week low of $60.255 on elevated volume (2.7× avg).
Summary
Globus Medical trimmed full-year 2026 revenue guidance to $3.09 billion from $3.18-$3.22 billion while reaffirming EPS guidance. Its board also added $500 million to the share repurchase program, leaving about $611 million available.
Key Events · Earnings and Guidance · GMED
-
2026 Revenue Guidance Cut to $3.09B
Full-year 2026 revenue guidance was lowered to $3.09 billion from the previous range of $3.18 billion to $3.22 billion, still representing 5.1% growth over fiscal 2025.
-
Q3 Sales Slip 0.7% to $763.7M
Worldwide net sales were $763.7 million, down 0.7% as reported and 0.5% in constant currency. Base business excluding Nevro rose 3.0% to $690.0 million, while international fell 5.7%.
-
EPS Guidance Reaffirmed at $4.95-$5.05
Non-GAAP fully diluted EPS guidance for fiscal 2026 was reaffirmed at $4.95 to $5.05, representing 24.4% to 26.9% growth over fiscal 2025; Q3 non-GAAP diluted EPS was $1.23, up 4.4%.
-
$500M Added to Share Repurchase Program
On November 2, 2026 the board authorized an additional $500.0 million of Class A common stock repurchases, leaving approximately $611.0 million available; the program has no expiration date.
Analysis · GMED · Industrial Applications And Services
The headline move is a revenue guidance cut to $3.09 billion from a prior $3.18-$3.22 billion range, even as non-GAAP EPS guidance of $4.95-$5.05 was reaffirmed. Lower sales with a held profit line implies margin expansion rather than volume growth. Third-quarter sales of $763.7 million fell 0.7% year over year, with U.S. Spine up only 2% against tough comparables and international down 5.7%. Offsetting the softer top line, the board added $500 million to the buyback, leaving roughly $611 million available, and the company generated record quarterly operating and free cash flow of $265.2 million and $224.8 million respectively. That tension — a trimmed revenue outlook paired with a bigger repurchase authorization — is the story: management is leaning on cash return while the core spine business digests a strong prior-year quarter.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GMED was trading at $80.31 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $10.9B. The 52-week trading range was $60.26 to $101.40. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.